Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dyne Therapeutics Inc DYN

Healthcare Biotechnology
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is... see more

Recent & Breaking News (NDAQ:DYN)

Dyne Therapeutics Announces CEO Transition

GlobeNewswire March 25, 2024

Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

GlobeNewswire March 13, 2024

Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire March 5, 2024

Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

GlobeNewswire February 14, 2024

Dyne Therapeutics to Present at February Investor Conferences

GlobeNewswire February 1, 2024

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

GlobeNewswire January 11, 2024

Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2024

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

GlobeNewswire January 4, 2024

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire January 3, 2024

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE(TM) Platform in Developing Therapeutics for Rare Muscle Diseases

GlobeNewswire January 3, 2024

Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

GlobeNewswire January 2, 2024

Dyne Therapeutics to Present at November Investor Conferences

GlobeNewswire November 7, 2023

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

GlobeNewswire October 30, 2023

Dyne Therapeutics to Present at October Investor Conferences

GlobeNewswire September 28, 2023

Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

GlobeNewswire September 20, 2023

Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

GlobeNewswire September 5, 2023

Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

GlobeNewswire August 3, 2023

Dyne Therapeutics to Present at Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101

GlobeNewswire May 25, 2023

Dyne Therapeutics' Preclinical Data Demonstrating FORCE(TM) Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting

GlobeNewswire May 17, 2023